---
title: "HALO.US (HALO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HALO.US/news.md"
symbol: "HALO.US"
name: "HALO.US"
parent: "https://longbridge.com/en/quote/HALO.US.md"
datetime: "2026-05-20T05:36:29.834Z"
locales:
  - [en](https://longbridge.com/en/quote/HALO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HALO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HALO.US/news.md)
---

# HALO.US (HALO.US) — Related News

### [Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares](https://longbridge.com/en/news/286408551.md)
*2026-05-14T11:30:14.000Z*
> Halozyme Therapeutics CEO Helen Torley sold 20,000 shares at $71.75 each, totaling $1.435 million, reducing her ownershi

### [Morgan Stanley Cuts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00](https://longbridge.com/en/news/286132103.md)
*2026-05-12T16:23:31.000Z*
> Morgan Stanley has lowered its price target for Halozyme Therapeutics (NASDAQ:HALO) from $96.00 to $93.00 while maintain

### [](https://longbridge.com/en/news/286125508.md)
*2026-05-12T15:11:57.000Z*
> Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results and

### [Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target](https://longbridge.com/en/news/286009811.md)
*2026-05-11T23:45:18.000Z*
> Analyst Brendan Smith of TD Cowen has reiterated a Buy rating on Halozyme, maintaining a price target of $96. He cites s

### [Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2026 Earnings Guidance](https://longbridge.com/en/news/286000530.md)
*2026-05-11T21:30:00.000Z*
> Halozyme Therapeutics (NASDAQ:HALO) has updated its FY 2026 earnings guidance, projecting EPS between 7.750-8.250, sligh

### [Halozyme Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 376.71 M](https://longbridge.com/en/news/285990458.md)
*2026-05-11T20:19:05.000Z*
### [HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE | HALO Stock News](https://longbridge.com/en/news/285987903.md)
*2026-05-11T12:01:00.000Z*
> Halozyme Therapeutics reported strong Q1 2026 results, with total revenue up 42% YOY to $377 million and a new $1 billio

### [Halozyme Therapeutics Earnings: What To Look For From HALO](https://longbridge.com/en/news/285827317.md)
*2026-05-10T03:06:44.000Z*
> Halozyme Therapeutics will announce earnings results on Monday after market close. Last quarter, it reported revenues of